<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="193283">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575952</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-9920</org_study_id>
    <secondary_id>NCI-2009-00623</secondary_id>
    <secondary_id>GOG-9920</secondary_id>
    <secondary_id>CDR0000580419</secondary_id>
    <secondary_id>GOG-9920</secondary_id>
    <secondary_id>GOG-9920</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00575952</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer</brief_title>
  <official_title>A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when
      given together with doxorubicin hydrochloride and cisplatin in treating patients with stage
      III-IV endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, doxorubicin
      hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving more than one drug
      (combination chemotherapy) and giving them in different ways may kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose of intraperitoneal (IP) paclitaxel when given
      concurrently with fixed dose intravenous (IV) doxorubicin (doxorubicin hydrochloride) and IV
      cisplatin.

      II. To determine the maximum tolerated dose of IP paclitaxel when given concurrently with
      fixed dose IV doxorubicin hydrochloride and IP cisplatin.

      III. To determine the feasibility of an IV/IP based doxorubicin hydrochloride, paclitaxel,
      and cisplatin chemotherapy regimen in patients with advanced endometrial cancer.

      OUTLINE: This is a dose-escalation study of paclitaxel.

      Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over
      1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim subcutaneously (SC) on
      days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses
      in the absence of disease progression or unacceptable toxicity.

      Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and
      paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of observed DLTs, defined as grade 3-4 hematologic or non-hematologic toxicity graded using CTCAE v3.0</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IV cisplatin, determined according to dose-limiting toxicities (DLTs) graded using CTCAE v3.0</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IP cisplatin, determined according to DLTs graded using CTCAE v3.0</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Endometrial Adenosquamous Carcinoma</condition>
  <condition>Endometrial Clear Cell Adenocarcinoma</condition>
  <condition>Endometrial Mixed Adenocarcinoma</condition>
  <condition>Endometrial Serous Adenocarcinoma</condition>
  <condition>Endometrial Squamous Cell Carcinoma</condition>
  <condition>Endometrial Undifferentiated Carcinoma</condition>
  <condition>Recurrent Uterine Corpus Carcinoma</condition>
  <condition>Stage IIIA Uterine Corpus Cancer</condition>
  <condition>Stage IIIC Uterine Corpus Cancer</condition>
  <condition>Stage IVA Uterine Corpus Cancer</condition>
  <condition>Stage IVB Uterine Corpus Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV or IP</description>
    <arm_group_label>Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>Filgrastim-sndz</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV or IP</description>
    <arm_group_label>Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>filgrastim-SD/01</other_name>
    <other_name>HSP-130</other_name>
    <other_name>Neulasta</other_name>
    <other_name>Neulastim</other_name>
    <other_name>Pegfilgrastim Biosimilar HSP-130</other_name>
    <other_name>SD-01</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stage IIIA, or stage IIIC with positive cytologic washings/ascites,
             adnexal spread, or serosal involvement, or stage IV (by virtue of intraperitoneal
             disease spread) histologically confirmed endometrial cancer (endometrioid, serous,
             clear cell, squamous/adenosquamous, undifferentiated, or mixed histologies)

          -  Patients must be optimally cytoreduced with less than or equal to 2 cm residual
             disease

          -  Absolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to
             Common Toxicity Criteria (Common Terminology Criteria for Adverse Events [CTCAE]
             version 3.0 [v3.0]) grade 1

          -  Platelets greater than or equal to 100,000/mm^3 (CTCAE v3.0 grade 0-1)

          -  Hemoglobin greater than or equal to 10 g/dl (CTCAE v3.0 grade 1)

          -  Creatinine less than or equal to 2 mg/% or 24 hour creatinine clearance &gt; 50 ml/min

          -  Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (CTCAE v3.0 grade
             1)

          -  Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 2.5 x ULN (CTCAE
             v3.0 grade 1)

          -  Neuropathy (sensory and motor) less than or equal to CTCAE v3.0 grade 1

          -  Patients must have normal ejection fraction

          -  Patients must be enrolled within 8 weeks of surgery

          -  Patients who have met the pre-entry requirements

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

          -  Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or
             2

        Exclusion Criteria:

          -  Metastatic disease involving lung or liver parenchyma, bone or inguinal or scalene
             lymph nodes

          -  Patients with GOG performance grade of 3 or 4

          -  Patients with concomitant medical illness such as serious uncontrolled infection,
             uncontrolled angina, or serious peripheral neuropathy, which in the opinion of the
             treating physician, makes the protocol prescribed treatments hazardous to the patient

          -  Patients with 3rd degree or complete heart block are not eligible unless a pacemaker
             is in place; patients who are on medications which alter cardiac conduction
             (digitalis, beta blockers, calcium channel blockers) or who have other cardiac
             conduction abnormalities may be placed on study at the discretion of the investigator

          -  Patients with a history of other invasive malignancies, with the exception of
             non-melanoma skin cancer, are excluded if there is any evidence of other malignancy
             being present within the last five years; patients are also excluded if their
             previous cancer treatment contraindicates this protocol therapy

          -  Patients who have received prior radiation or chemotherapy for the cancer being
             treated in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. McMeekin</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central Connecticut</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Hospital University Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 26, 2016</lastchanged_date>
  <firstreceived_date>December 15, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
